Gene Therapy Stocks Rally as Safety Concerns Ease for Bluebird, Peers

Gene therapy trials involved cancer diagnoses in patients with sickle cell disease and hemophilia, though investigations determined these were unrelated to treatment.

In the long and halting effort to rewrite the human genetic code as medicine, fear is as powerful a force as science itself. This June, federal regulators cleared Bluebird Bio to resume clinical trials for sickle cell disease and beta-thalassemia after a four-month pause triggered by cancer diagnoses in trial participants — diagnoses that, upon investigation, proved unrelated to the therapy. The reprieve offered a quiet but meaningful signal: that the promise of gene therapy, so often shadowed by its own fraught history, had not yet been extinguished.

Gene Therapy Stocks Rally as Safety Concerns Ease for Bluebird, Peers

Cobertura Relacionada

Receba o Register no seu e-mail